FOLH1 and prostate carcinoma: The overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer cells is the rationale for radioligand therapy using small-molecule inhibitors with high affinity to PSMA, such as PSMA-617, commonly labelled with beta-emitting 177Lutetium (LuPSMA-RLT).